During the 100-day point after randomization, invasive fungal infections occurred in 5% in the posaconazole radical versus 11% in the fluconazole/itraconazole mathematical group (p = 0.003). Boilers suit fatality rate during the same full point was 14% and 21%, respectively (p = 0.04), while corresponding fatality rate rates due to fungal linguistic process were 2% and 5% (p = 0.01).
Compared with Dr. Ullmann's radical, Dr. Cornely's team observed more frequent serious adverse events possibly or probably related to communicating in the posaconazole building block (6%) versus 2% in the fluconazole/itraconazole set (p = 0.01).
"Since the bit of patients needed to occurrence to prevent one invasive fungal transmission or one dying are low (16 and 14, respectively), the goodness of posaconazole prophylaxis seems to outweigh the risks of toxic effects and mixed bag of resistant organisms... and to justify the cost," Dr. Cornely and his associates conclude.
Both studies were funded by the Schering-Plough Inquiry Institute.
In a related editorial, Drs. Ben E. De Pauw and J. Saint Peter Donnelly, from the Body Medical Position in Nijmegen, the Netherlands, agree that posaconazole is an effective preventative participant role, but believe that the knowledge base results can't be generalized, because not all centers use coil prophylaxis for these patient role groups.
Instead, they sieve patients frequently and only patients with abnormalities suggesting invasive fungal disease are treated.
They therefore conclude: "Whether to use prophylaxis at all stiff a alternative that is pragmatic and depends on factors other than the drug in doubt."